Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D.

N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1903765. [Epub ahead of print]

PMID:
31166679
2.

Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.

Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH.

Breast Cancer Res Treat. 2019 Jun 1. doi: 10.1007/s10549-019-05292-y. [Epub ahead of print]

PMID:
31154579
3.

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C.

Nat Commun. 2019 May 30;10(1):2433. doi: 10.1038/s41467-019-10456-x.

4.

Airway management in a patient of Crouzon syndrome for maxillo-facial reconstructive surgery: Role of point-of-care ultrasonography.

Tripathy DK, Dhar M, Haran GH, Chauhan U.

Indian J Anaesth. 2019 May;63(5):409-410. doi: 10.4103/ija.IJA_864_18. No abstract available.

5.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.

Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA.

Cancers (Basel). 2019 May 24;11(5). pii: E714. doi: 10.3390/cancers11050714. Review.

6.

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT.

Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17.

PMID:
31097774
7.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J.

Future Oncol. 2019 May 10. doi: 10.2217/fon-2019-0180. [Epub ahead of print]

8.

Pedunculated poorly differentiated papillary sebaceous carcinoma of the eyelid.

Tripathy D, Bothra N, Mittal R.

Orbit. 2019 Apr 25:1-2. doi: 10.1080/01676830.2019.1600149. [Epub ahead of print] No abstract available.

PMID:
31020881
9.

External dacryocystorhinostomy for isolated lacrimal sac rhinosporidiosis - A suitable alternative to dacryocystectomy.

Bothra N, Rath S, Mittal R, Tripathy D.

Indian J Ophthalmol. 2019 May;67(5):665-668. doi: 10.4103/ijo.IJO_1136_18.

10.

Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2019 Jul;176(1):251. doi: 10.1007/s10549-019-05218-8.

PMID:
30982934
11.

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).

Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK.

Breast Cancer Res Treat. 2019 Jul;176(1):227-234. doi: 10.1007/s10549-018-05081-z. Epub 2019 Apr 11.

PMID:
30977027
12.

Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model.

Fujii T, Mason J, Chen A, Kuhn P, Woodward WA, Tripathy D, Newton PK, Ueno NT.

Oncologist. 2019 Apr 5. pii: theoncologist.2018-0713. doi: 10.1634/theoncologist.2018-0713. [Epub ahead of print]

PMID:
30952823
13.

Bioprospection of anti-inflammatory phytochemicals suggests rutaecarpine and quinine as promising 15-lipoxygenase inhibitors.

Gurung AB, Pamay P, Tripathy D, Biswas K, Chatterjee A, Joshi SR, Bhattacharjee A.

J Cell Biochem. 2019 Aug;120(8):13598-13613. doi: 10.1002/jcb.28634. Epub 2019 Apr 1.

PMID:
30937959
14.

What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer.

Whisenant MS, Strunk FA, Tripathy D, Williams LA.

Support Care Cancer. 2019 Apr 2. doi: 10.1007/s00520-019-04770-9. [Epub ahead of print]

PMID:
30937601
15.

Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L, Spicer D, Buchanan TA, Mortimer JE, Dieli-Conwright CM.

JAMA Oncol. 2019 Mar 28. doi: 10.1001/jamaoncol.2019.0038. [Epub ahead of print]

PMID:
30920602
16.

Ocular Adnexal Racemose Cysticercosis Masquerading as Dermoid Cyst.

Bothra N, Mittal R, Pradhan A, Tripathy D.

Ophthalmic Plast Reconstr Surg. 2019 Mar 12. doi: 10.1097/IOP.0000000000001365. [Epub ahead of print] No abstract available.

PMID:
30882589
17.

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.

Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K.

Clin Cancer Res. 2019 Mar 13. doi: 10.1158/1078-0432.CCR-18-3274. [Epub ahead of print]

PMID:
30867218
18.

Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.

Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M.

Breast Cancer Res Treat. 2019 Jun;175(3):667-674. doi: 10.1007/s10549-019-05181-4. Epub 2019 Mar 5.

PMID:
30835017
19.

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2019 Jun;175(2):339-351. doi: 10.1007/s10549-019-05166-3. Epub 2019 Mar 2. Erratum in: Breast Cancer Res Treat. 2019 Apr 15;:.

PMID:
30826934
20.

Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants.

Tripathy D, Merovci A, Basu R, Abdul-Ghani M, DeFronzo RA.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2842-2850. doi: 10.1210/jc.2018-02304.

PMID:
30789980
22.

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.

Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH.

Breast Cancer Res Treat. 2019 Feb 15. doi: 10.1007/s10549-019-05165-4. [Epub ahead of print] Erratum in: Breast Cancer Res Treat. 2019 Jun 1;:.

PMID:
30771047
23.

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C.

Nat Commun. 2019 Feb 8;10(1):657. doi: 10.1038/s41467-019-08593-4. Erratum in: Nat Commun. 2019 May 30;10(1):2433.

24.

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.

Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L.

Breast Cancer Res Treat. 2019 May;175(1):5-15. doi: 10.1007/s10549-018-05102-x. Epub 2019 Jan 22. Review.

25.

Secondary metabolite profiling, cytotoxicity, anti-inflammatory potential and in vitro inhibitory activities of Nardostachys jatamansi on key enzymes linked to hyperglycemia, hypertension and cognitive disorders.

Bose B, Tripathy D, Chatterjee A, Tandon P, Kumaria S.

Phytomedicine. 2019 Mar 1;55:58-69. doi: 10.1016/j.phymed.2018.08.010. Epub 2018 Aug 8.

PMID:
30668444
26.

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.

Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M.

Clin Cancer Res. 2019 Apr 15;25(8):2433-2441. doi: 10.1158/1078-0432.CCR-18-2366. Epub 2018 Dec 28.

PMID:
30593513
27.

CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer.

Ring A, Nguyen C, Smbatyan G, Tripathy D, Yu M, Press M, Kahn M, Lang JE.

Cancers (Basel). 2018 Dec 19;10(12). pii: E525. doi: 10.3390/cancers10120525.

28.

Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.

Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.

Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12. Review.

PMID:
30542816
29.

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5.

PMID:
30518672
30.

Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise in survivors of breast cancer.

Dieli-Conwright CM, Sweeney FC, Courneya KS, Tripathy D, Sami N, Lee K, Buchanan TA, Spicer D, Bernstein L, Mortimer JE, Demark-Wahnefried W.

Cancer. 2019 Mar 15;125(6):910-920. doi: 10.1002/cncr.31879. Epub 2018 Nov 30.

PMID:
30500981
31.

Immunotoxicity of titanium dioxide nanoparticles via simultaneous induction of apoptosis and multiple toll-like receptors signaling through ROS-dependent SAPK/JNK and p38 MAPK activation.

Dhupal M, Oh JM, Tripathy DR, Kim SK, Koh SB, Park KS.

Int J Nanomedicine. 2018 Oct 23;13:6735-6750. doi: 10.2147/IJN.S176087. eCollection 2018.

32.

Detection of Fowlpox virus carrying distinct genome segments of Reticuloendotheliosis virus.

Joshi LR, Bauermann FV, Hain KS, Kutish GF, Armién AG, Lehman CP, Neiger R, Afonso CL, Tripathy DN, Diel DG.

Virus Res. 2019 Jan 15;260:53-59. doi: 10.1016/j.virusres.2018.10.017. Epub 2018 Oct 22.

PMID:
30359622
33.

Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial.

Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, Stewart C, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE.

Breast Cancer Res. 2018 Oct 19;20(1):124. doi: 10.1186/s13058-018-1051-6.

34.

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.

Kono M, Fujii T, Matsuda N, Harano K, Chen H, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT.

J Cancer. 2018 Sep 8;9(19):3640-3646. doi: 10.7150/jca.26825. eCollection 2018.

35.

Overall survival in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D.

BMJ Support Palliat Care. 2018 Sep 22. pii: bmjspcare-2018-001516. doi: 10.1136/bmjspcare-2018-001516. [Epub ahead of print]

PMID:
30244203
36.

Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.

Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L.

Breast Cancer Res Treat. 2019 Jan;173(1):1-9. doi: 10.1007/s10549-018-4969-6. Epub 2018 Sep 21.

PMID:
30242579
37.

Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance.

Shannon C, Merovci A, Xiong J, Tripathy D, Lorenzo F, McClain D, Abdul-Ghani M, Norton L, DeFronzo RA.

Diabetes. 2018 Dec;67(12):2507-2517. doi: 10.2337/db18-0439. Epub 2018 Sep 13.

38.

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK.

Oncologist. 2019 Mar;24(3):313-318. doi: 10.1634/theoncologist.2018-0213. Epub 2018 Aug 23.

PMID:
30139836
39.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Dec;18(6):e1283-e1288. doi: 10.1016/j.clbc.2018.07.008. Epub 2018 Jul 10.

PMID:
30077429
40.

Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.

Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25.

41.

High-Resolution Anterior Segment Optical Coherence Tomography in Intraepithelial Versus Invasive Ocular Surface Squamous Neoplasia.

Singh S, Mittal R, Ghosh A, Tripathy D, Rath S.

Cornea. 2018 Oct;37(10):1292-1298. doi: 10.1097/ICO.0000000000001680.

PMID:
29985794
42.

Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.

Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT.

Breast Cancer Res Treat. 2018 Sep;171(2):501-511. doi: 10.1007/s10549-018-4853-4. Epub 2018 Jun 18.

PMID:
29915946
43.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

44.

RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.

Lang JE, Ring A, Porras T, Kaur P, Forte VA, Mineyev N, Tripathy D, Press MF, Campo D.

Ann Surg Oncol. 2018 Aug;25(8):2261-2270. doi: 10.1245/s10434-018-6540-4. Epub 2018 Jun 4.

45.

Reply to E. Parkin et al.

Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE.

J Clin Oncol. 2018 Jul 10;36(20):2129-2130. doi: 10.1200/JCO.2018.78.7754. Epub 2018 May 30. No abstract available.

PMID:
29847294
46.

Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.

Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H.

Ann Diagn Pathol. 2018 Aug;35:69-76. doi: 10.1016/j.anndiagpath.2018.04.004. Epub 2018 May 3.

47.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
48.

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.

Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A.

Breast Cancer Res Treat. 2018 Sep;171(2):325-334. doi: 10.1007/s10549-018-4828-5. Epub 2018 May 22.

PMID:
29789969
49.

Comparison of landmark versus pre-procedural ultrasonography-assisted midline approach for identification of subarachnoid space in elective caesarean section: A randomised controlled trial.

Dhanger S, Vinayagam S, Vaidhyanathan B, Rajesh IJ, Tripathy DK.

Indian J Anaesth. 2018 Apr;62(4):280-284. doi: 10.4103/ija.IJA_488_17.

50.

Comparison of Postoperative Analgesic Efficacy of Wound Site Infiltration and Ultrasound-guided Transversus Abdominis Plane Block with 0.5% Ropivacaine in Lower Abdominal Surgeries under Spinal Anesthesia.

Pratheeba N, Remadevi R, Raajesh IJ, Bhavani V, Tripathy DK, Bhat RR.

Anesth Essays Res. 2018 Jan-Mar;12(1):80-84. doi: 10.4103/aer.AER_201_17.

Supplemental Content

Loading ...
Support Center